1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Magle Chemoswed Holding AB

Magle Chemoswed Holding AB

0.27
SEK
-0.02
(-5.56%)
-8.23EPS
21.48MMarket Cap
Nov 02Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10.38
12.5
18.71
12.31
13.49
15.83
18.49
13.01
14.08
Basic EPS, GAAP
-0.32
0.07
0.24
0.4
0.85
1.13
0.49
-12.23
-8.23
Free Cash Flow per Basic Share
-0.97
-6.07
-2.36
1.32
-0.41
0.02
-2.18
-3.3
-5.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.96
11.13
11.57
12.81
13.54
14.59
27.05
14.51
12.61
Tangible Book Value per Share
3.77
8.39
8.65
5.65
5.93
6.89
11.76
2.52
1.07
Basic Weighted Avg Shares
10
10
8
11
11
11
13
21
21
Sales/Revenue/Turnover
106
128
142
132
146
170
236
268
291
Operating Margin (%)
-3.67
0.82
3.43
3.8
10.16
10.8
3.77
-87.69
-48.58
Depreciation Expense
7
13
12
12
13
13
28
191
101
Net Income, GAAP
-3
1
2
4
9
12
6
-252
-170
Effective Tax Rate (%)
- -
29.73
25.23
22.22
17.04
19.33
- -
- -
- -
Profit Margin (%)
-3.08
0.59
1.28
3.24
6.28
7.14
2.66
-93.95
-58.44
Working Capital
-22
-8
17
9
14
11
-162
-277
-302
LT Debt
- -
8
32
30
34
37
77
24
20
Total Equity
51
114
116
139
147
158
555
300
260
Return on Invested Capital (%)
- -
0.1
2.22
2.34
5.56
6.84
- -
- -
- -
Return on Capital (%)
- -
1.01
1.64
3
5.7
7.1
- -
- -
- -
Return on Common Equity (%)
- -
0.91
1.58
3.36
6.4
7.98
1.76
-58.93
-43.03

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
359
43
324
LT Borrowings
290
292
- -
LT Finance Leases
24
22
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
363
84
21

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
187
179
199
Cash, Cash Equivalents & STI
14
- -
2
Accounts Receivable, Net
39
31
41
Inventories
90
93
104
Total Current Liabilities
464
151
501
Payables & Accruals
- -
- -
- -
ST Debt
359
43
324
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.55%
-46.02%
Free Cash Flow
- -
-2,736.67%
144.47%
Net Income, GAAP
- -
-776.25%
-4,114.78%
Sales/Revenue/Turnover
- -
14.42%
13.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
46
65
87
236
2025
81
52
71
78
268
2026
69
73
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.27
0.01
0.89
-0.04
0.49
2025
-0.06
-1.35
0.15
-6.49
-12.23
2026
-1.07
-0.82
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Aaron Michael Wong
Full Time Employees
144
Sector
Health technology
Industry
Biotechnology
Address
Agneslundsvägen 27 Malmö SN Sweden 212 15
IPO Date
Jun 30, 2020
Website
maglechemoswed.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Magle Chemoswed Holding AB (publ) (MAGLE.ST) is a Sweden-based holding company that operates as a contract development and manufacturing organization (CDMO) serving the pharmaceutical and medical device industries; it conducts research, development, and manufacturing in pharmaceutical chemistry and technology through subsidiaries including Magle Chemoswed AB, Adroit Science AB, Magle PharmaCept, and Magle Biopolymers A/S. The company provides comprehensive services from analytical development, including methods for product release and characterization; process development; solid-state expertise in crystallization, polymorph screening, salt formation, and particle engineering; cGMP and ISO 13485-compliant manufacturing in five dedicated suites; fill-and-finish operations for small-scale vial filling; and inhalation drug administration support; it specializes in active pharmaceutical ingredients (APIs) such as warfarin sodium (anticoagulant), melperone hydrochloride (antipsychotic), isradipine (calcium channel blocker for hypertension), amantadine sulfate (for central nervous system disorders), and benserazide hydrochloride (for Parkinson's disease treatment); it also offers custom synthesis and modification of dextran derivatives for drug delivery, medical devices, and diagnostics, alongside consultancy in material characterization and solid-phase analysis. Founded in 1944 and headquartered in Malmö, Sweden, Magle Chemoswed Holding employs approximately 158 people and targets pharmaceutical companies globally with GMP-compliant, regulatory-ready solutions meeting EMA and FDA standards. Recent developments include the 2024 merger with Amniotics and pK Chemicals to expand contract development and manufacturing capabilities; the April 2025 completion of the acquisition of all shares in Saving Chlora AB; and a December 2025 strategic distribution agreement with Rifa Pharma for SmartPAN and SmartGEL products in India, enhancing market presence in embolization and wound care technologies.